Light-Based therapy may tame kidney transplant rejection
NCT ID NCT07663669
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study looks at whether a treatment called extracorporeal photopheresis can help kidney transplant recipients whose bodies are rejecting the new organ. The treatment involves filtering the patient's blood, treating it with a light-activated drug, and returning it to the body. Researchers will track kidney function over one year to see if the therapy stabilizes or slows the decline in kidney health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- extracorporeal photopheresis
- What this could lead to
- If effective, this approach could offer a way to control antibody-mediated rejection in kidney transplant patients without increasing immunosuppression.
- What could go wrong
- This is a small, observational study with no control group, so results may not prove cause and effect. The treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire de Besançon
RECRUITINGBesançon, 25000, France